等待開盤 02-05 09:30:00 美东时间
-0.130
-2.02%
The multi-analyte test previously received Breakthrough Device Designation from the FDA, a program intended to accelerate the development and review of devices that provide for more effective treatment or diagnosis of
02-03 21:37
Quanterix Submits FDA 510(k) Application for Multi-Analyte Blood Test for Alzheimer's Detection Quanterix Corporation has announced the submission of a 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) for its multi-analyte algorithmic blood test designed for Alzheimer's d
02-03 21:33
Analysis of Subjective Cognitive Decline (SCD) cohort indicates that combining biomarkers representing four key biological axes—amyloid, tau, neurodegeneration, and neuroinflammation—provides a superior window into
01-21 21:38
Quanterix Unveils Landmark Study Showing Multi-Biomarker Blood Test Improves Early Alzheimer’s Risk Profiling Quanterix Corporation has announced the publication of a new clinical study in JAMA Network Open, led by researchers at Amsterdam UMC, which followed a cohort of nearly 300 individuals for u
01-21 21:33
Illumina (ILMN) shares fell on Friday after its chief commercial officer, Everett Cunningham, resigned to lead the rival life sciences company Quanterix (QTRX), while former NIH genomics director Eric...
01-10 00:51
U.S. stocks were higher, with the Dow Jones index gaining around 200 points on ...
01-10 00:25
Update: Includes share move, guidance commentary Quanterix (QTRX) shares surged 25% Friday after the company announced a CEO transition alongside an upbeat update indicating it expects to exceed its f...
01-09 23:05
Quanterix ( ($QTRX) ) has provided an update. On January 8, 2026, Quanterix ann...
01-09 06:19
Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that its Board of Directors
01-09 05:33
今日重点评级关注:Ascendiant Capital:维持SurgePays Inc"买入"评级,目标价从9.5美元升至9.75美元;Ascendiant Capital:维持Outlook Therapeutics"买入"评级,目标价从8美元升至10美元
2025-12-23 12:32